Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Feb;9(2):e002376.
doi: 10.1161/CIRCINTERVENTIONS.114.002376.

Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial

Marlon I Spreen  1 , Jasper M Martens  1 , Bettina E Hansen  1 , Bob Knippenberg  1 , Elke Verhey  1 , Lukas C van Dijk  1 , Jean-Paul P M de Vries  1 , Jan-Albert Vos  1 , Gert Jan de Borst  1 , Evert-Jan P A Vonken  1 , Jan J Wever  1 , Randolph G Statius van Eps  1 , Willem P Th M Mali  1 , Hans van Overhagen  2
Affiliations
Randomized Controlled Trial

Percutaneous Transluminal Angioplasty and Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia (PADI) Trial

Marlon I Spreen et al. Circ Cardiovasc Interv. 2016 Feb.

Abstract

Background: Endovascular infrapopliteal treatment of patients with critical limb ischemia using percutaneous transluminal angioplasty (PTA) and bail-out bare metal stenting (BMS) is hampered by restenosis. In interventional cardiology, drug-eluting stents (DES) have shown better patency rates and are standard practice nowadays. An investigator-initiated, multicenter, randomized trial was conducted to assess whether DES also improve patency and clinical outcome of infrapopliteal lesions.

Methods and results: Adults with critical limb ischemia (Rutherford category ≥4) and infrapopliteal lesions were randomized to receive PTA±BMS or DES with paclitaxel. Primary end point was 6-month primary binary patency of treated lesions, defined as ≤50% stenosis on computed tomographic angiography. Stenosis >50%, retreatment, major amputation, and critical limb ischemia-related death were regarded as treatment failure. Severity of failure was assessed with an ordinal score, ranging from vessel stenosis through occlusion to the clinical failures. Seventy-four limbs (73 patients) were treated with DES and 66 limbs (64 patients) received PTA±BMS. Six-month patency rates were 48.0% for DES and 35.1% for PTA±BMS (P=0.096) in the modified-intention-to-treat and 51.9% and 35.1% (P=0.037) in the per-protocol analysis. The ordinal score showed significantly worse treatment failure for PTA±BMS versus DES (P=0.041). The observed major amputation rate remained lower in the DES group until 2 years post-treatment, with a trend toward significance (P=0.066). Less minor amputations occurred after DES until 6 months post-treatment (P=0.03).

Conclusions: In patients with critical limb ischemia caused by infrapopliteal lesions, DES provide better 6-month patency rates and less amputations after 6 and 12 months compared with PTA±BMS.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00471289.

Keywords: angioplasty; drug-eluting stents; ischemia; peripheral arterial disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flow chart, modified-intention-to-treat population. BMS indicates bare metal stent; CLI, critical limb ischemia; CTA, computed tomographic angiography; DES, drug-eluting stent; DSA, digital subtraction angiography; FU, follow-up; and PTA, percutaneous transluminal angioplasty. *Four patients included for 2 limbs with 1 limb in each arm. †One of these patients died before 1 year FU. ‡Two of these patients died before 1 year FU.
Figure 2.
Figure 2.
Kaplan–Meier curves representing the estimated 2-year cumulative incidence rates of major amputation per limb after percutaneous transluminal angioplasty (PTA)±bare metal stent (BMS) and drug-eluting stent (DES).
Figure 3.
Figure 3.
Kaplan–Meier curves representing the estimated 2-year cumulative incidence rates of survival per patient after percutaneous transluminal angioplasty (PTA)±bare metal stent (BMS) and drug-eluting stent (DES).
Figure 4.
Figure 4.
Kaplan–Meier curves representing the estimated 2-year cumulative incidence rates of major amputation or death per limb after percutaneous transluminal angioplasty (PTA)±bare metal stent (BMS) and drug-eluting stent (DES).
Figure 5.
Figure 5.
Mean Rutherford categories at baseline, 6 and 12 months. BMS indicates bare metal stent; CI, confidential interval; DES, drug-eluting stent; and PTA, percutaneous transluminal angioplasty.
Figure 6.
Figure 6.
Mean ankle-brachial index at baseline, 6 and 12 months. BMS indicates bare metal stent; CI, confidential interval; DES, drug-eluting stent; and PTA, percutaneous transluminal angioplasty.
Figure 7.
Figure 7.
Mean toe pressure at baseline, 6 and 12 months. BMS indicates bare metal stent; CI, confidential interval; DES, drug-eluting stent; and PTA, percutaneous transluminal angioplasty.
See this image and copyright information in PMC

References

    1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67. doi: 10.1016/j.jvs.2006.12.037. - PubMed
    1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr, White CJ, White J, White RA, Antman EM, Smith SC, Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B American Association for Vascular Surgery/Society for Vascular Surgery; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society of Interventional Radiology; ACC/AHA Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)–summary of recommendations. J Vasc Interv Radiol. 2006;17:1383–1397, quiz 1398. doi: 10.1097/01.RVI.0000240426.53079.46. - PubMed
    1. Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H BASIL Trial Participants. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005;366:1925–1934. doi: 10.1016/S0140-6736(05)67704-5. - PubMed
    1. Nehler MR, Coll JR, Hiatt WR, Regensteiner JG, Schnickel GT, Klenke WA, Strecker PK, Anderson MW, Jones DN, Whitehill TA, Moskowitz S, Krupski WC. Functional outcome in a contemporary series of major lower extremity amputations. J Vasc Surg. 2003;38:7–14. - PubMed
    1. van Overhagen H, Spiliopoulos S, Tsetis D. Below-the-knee interventions. Cardiovasc Intervent Radiol. 2013;36:302–311. doi: 10.1007/s00270-013-0550-1. - PubMed

Publication types

Substances

Associated data